Typhoid conjugate vaccine demonstrates strong safety and immunogenicity in Phase III trial

Phase III results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj. Multi-dose, demonstrate that it is safe and immunogenic in typhoid-endemic populations in sub-Saharan Africa. EuTYPH-C Inj. Multi-dose is manufactured by EuBiologics Co., LTD, Republic of Korea.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup